NanoViricides Inc. (NNVC) Adds Drug Candidate to Anti-influenza Therapeutics Program, Prepares for FDA Submission
NanoViricides Inc. yesterday announced it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide™ anti-influenza therapeutics program. Based on NV-INF-1's demonstrated efficacy as a highly effective anti-influenza drug in animal studies, NanoViricides said it believes the candidate will be rapidly and widely recognized as treatment for severe influenza. FDA consultants are assisting the company in developing additional information on NV-INF-1 to prepare for the pre-IND application to the FDA. NV-INF-1 is expected to be effective against most strains and types of influenzas, including novel epidemic influenza strains such as the swine flu; seasonal…